USNA
USANA Health SciencesCAI scenario view
RankAlpha Sentiment CodexThe current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
AI commentary
Post-earnings news tone is mixed-negative: the company reiterated its long-term transformation thesis, but the Q2 release disclosed weaker venture performance and a major guidance reduction. The latest packet anchor is $14.89 on August 6; a verified post-print percentage reaction, analyst revisions, and social coverage are unavailable. Low coverage and loose peers warrant monitoring rather than a high-conviction directional call.
Evidence flagged
No evidence quality warning is currently attached to this memo.
AI events
Q2 net sales fell 5% year over year to $223 million, adjusted EPS was negative $0.07, and fiscal 2026 guidance was reduced materially, including updated consolidated sales of $910 million and adjusted EPS of $0.76 [#SEC-8K-2026-08-04]. Near-term sentiment and estimates may remain pressured.
Core Nutritional results were described as generally in line with expectations; Greater China sales increased 1% year over year, but core active customers declined 8% and Greater China active customers declined 6% [#SEC-8K-2026-08-04]. The next operating update must show customer and revenue stabilization.
Management continues to invest in product innovation, Brand Partner incentives, channel expansion, and technology modernization. Hiya and Rise remain potential long-term growth engines, but Hiya revenue and subscribers fell 17% year over year and Rise experienced a packaging disruption [#SEC-8K-2026-08-04].
Recommendation
No formal recommendation provided.

